Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-139

at this very time 22 mill is a ‘lifesaver’ in one sense, sp steady with a nice ‘premium’ to pre suspension sp, dilution would have seen the sp at what level?

quite right in seeing the big picture, it equates to two quarters of cash burn, albeit take into account the potential extra 12 mill windfall.

you may be quite right on your gut feelings, of a future potential announcement, TAVR deal may be the catalyst to turn around the fortunes of this company, current market sp most definitely indicative of a wait and watch future events unfold.

TAVR deal should certainly change sentiment, minus of perhaps giving the Lions share to a partner, most positive of not having to fund R&D from future revenue, add into the mix those funds then advancing the Adapt IP tech.

@linebreaker, most flattered, and also MOST underserving of even being mentioned in the same breath as Tolstoy, however disparagingly!

ps; Wass a reply to wessomart.